The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns
as healthcare stocks have gained 14.7% over the past six months while the S&P 500 was up 9.9%.
As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional strategy at the start of the year, arrives at a moment of heightened market sensitivity, as
As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and chronic shortages has evolved into a highly competitive, government-influenced market where affordability and accessibility have finally taken center
Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, well below the S&P 500’s 11.2% gain. This may have investors wondering how to approach the situation.
The long-standing dominance of Pharmacy Benefit Managers (PBMs) in the American healthcare system has reached a critical inflection point as 2025 draws to a close. For decades, these "middlemen" operated in the shadows, negotiating drug prices and rebates with manufacturers while managing prescription benefits for millions. However, a relentless wave
As the curtain closes on 2025, the investment community is witnessing a significant shift in sentiment regarding the managed care sector. Cigna Group (NYSE: CI) has become the centerpiece of this narrative, receiving a wave of analyst upgrades to ‘Buy’ in the final weeks of December. Market experts are increasingly
As of December 18, 2025, Chubb Limited (NYSE: CB) stands as the preeminent titan of the global property and casualty (P&C) insurance landscape. With a market capitalization surging toward $120 billion and a reputation for ruthless underwriting discipline, the Zurich-domiciled insurer has become a cornerstone of institutional portfolios—most notably that of Warren Buffett’s Berkshire Hathaway. [...]
Date: December 15, 2025 1. Introduction Bristol Myers Squibb (BMS) (NYSE: BMY) is a global biopharmaceutical powerhouse focused on discovering, developing, manufacturing, and distributing innovative medicines for serious diseases. As of December 15, 2025, BMS stands at a critical juncture, balancing the impending "patent cliff" for several of its blockbuster drugs with a strategically diversified [...]
Over the last six months, Cigna’s shares have sunk to $276.25, producing a disappointing 12.1% loss - a stark contrast to the S&P 500’s 13% gain. This may have investors wondering how to approach the situation.
What a brutal six months it’s been for Molina Healthcare. The stock has dropped 42.1% and now trades at $168.08, rattling many shareholders. This was partly due to its softer quarterly results and might have investors contemplating their next move.
The latest Job Openings and Labor Turnover Survey (JOLTS) data, released on December 9, 2025, for the month of October, presents a nuanced picture of the U.S. labor market. While a slight uptick in job openings might offer a glimmer of resilience, the overarching trends of stagnant hiring and
